Genetically modified IL-2 bone marrow-derived myeloid cells reprogram the glioma immunosuppressive tumormicroenvironment
A. Canella, M. Nazzaro, S. Rajendran, C. Schmitt, A. Haffey, G. Nigita, D. Thomas, H. Wrightnour, P. Fadda, E. R. Mardis, T. P. Cripe, P. Rajappa
This study shows that genetically modified myeloid cells releasing IL-2 can reprogram the glioma tumor microenvironment to enhance anti-tumor immunity in a mouse model.
bioRxiv · Oct 19, 2022 · PreprintCancer Biology